Assignee
VIROGIN BIOTECH CANADA LTD
CA·5 granted patents·15 pending applications·1 citations·filing 2016–2024
Top patents by PatentIndex Score
20 records- 0190US12208126B2Oncolytic viral vectors and uses thereofVIROGIN BIOTECH CANADA LTD·Filed 2023·Granted Jan 28, 2025·1 cites·23 claims
- 0276US2024207334A1Oncolytic viral delivery of therapeutic polypeptidesVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 0368US2025243252A1Oncolytic herpes simplex virus vectors expressing immune system-stimulatory moleculesVIROGIN BIOTECH CANADA LTD·Filed 2024·Application pending·0 cites
- 0467US11865081B2Oncolytic viral delivery of therapeutic polypeptidesVIROGIN BIOTECH CANADA LTD·Filed 2018·Granted Jan 9, 2024·0 cites·14 claims
- 0561US2025304999A1Genetically modified enterovirus vectors with enhanced genomic stabilityVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 0661US2023365994A1Hsv vectors with enhanced replication in cancer cellsVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 0758US2025049867A1Engineered oncolytic herpesvirusesVIROGIN BIOTECH CANADA LTD·Filed 2022·Application pending·0 cites
- 0858US2022096578A1Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virusVIROGIN BIOTECH CANADA LTD·Filed 2021·Application pending·0 cites
- 0957US2026077006A1Oncolytic virus expressing an immune cell engager for tumor targetingVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 1054US2023279077A1Anti-glycoprotein d antibodies, methods of preparation, and uses thereofVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 1153US12162919B2Oncolytic herpes simplex virus vectors expressing immune system-stimulatory moleculesVIROGIN BIOTECH CANADA LTD·Filed 2017·Granted Dec 10, 2024·0 cites·18 claims
- 1252US11384119B2Compositions and methods for inhibiting CD279 interactionsVIROGIN BIOTECH CANADA LTD·Filed 2020·Granted Jul 12, 2022·0 cites·3 claims
- 1350US2026091069A1Transcriptional and translational dual regulated oncolytic herpes simplex virus vectorsVIROGIN BIOTECH CANADA LTD·Filed 2022·Application pending·0 cites
- 1444US2022267799A1Genetically modified enterovirus vectorsVIROGIN BIOTECH CANADA LTD·Filed 2020·Application pending·0 cites
- 1540US10590169B2Compositions and methods for inhibiting CD279 interactionsVIROGIN BIOTECH CANADA LTD·Filed 2016·Granted Mar 17, 2020·0 cites·10 claims
- 1639US2019307820A1Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virusVIROGIN BIOTECH CANADA LTD·Filed 2017·Application pending·0 cites
- 1739US2019106709A1Hsv vectors with enhanced replication in cancer cellsVIROGIN BIOTECH CANADA LTD·Filed 2017·Application pending·0 cites
- 1839US2021046130A1Recombinant viral vaccinesVIROGIN BIOTECH CANADA LTD·Filed 2019·Application pending·0 cites
- 1934US2020171110A1Hsv vector with reduced neurotoxicityVIROGIN BIOTECH CANADA LTD·Filed 2019·Application pending·0 cites
- 2034US2021177921A1Targeting moiety-decorated oncolytic virusesVIROGIN BIOTECH CANADA LTD·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VIROGIN BIOTECH CANADA LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →